[go: up one dir, main page]

TR200800692T2 - Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi. - Google Patents

Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.

Info

Publication number
TR200800692T2
TR200800692T2 TR2008/00692T TR200800692T TR200800692T2 TR 200800692 T2 TR200800692 T2 TR 200800692T2 TR 2008/00692 T TR2008/00692 T TR 2008/00692T TR 200800692 T TR200800692 T TR 200800692T TR 200800692 T2 TR200800692 T2 TR 200800692T2
Authority
TR
Turkey
Prior art keywords
treatment
myelin
conditions
diseases
losing
Prior art date
Application number
TR2008/00692T
Other languages
English (en)
Inventor
Michel Rathbone P.
Rampe David
Petty Margaret
Craig Smith P.
Original Assignee
Aventis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals, Inc. filed Critical Aventis Pharmaceuticals, Inc.
Publication of TR200800692T2 publication Critical patent/TR200800692T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formül Fin N-(piridil)-1 H-indol-1 -aminleri, potasyum ve sodyum kanallarının her ikisi için, benzersiz bir kapayıcı özellikler kombinasyonu sağlamaktadır. Bu bileşikler Çoklu Skleroz, Omurilik Yaralanması, Travmatik Beyin Yaralanması ve Felç gibi Miyelin Kaybettiren, Hastalıkların ve Durumların tedavisi için yararlıdırlar. Bileşikler ayrıca Felç Rehabilitasyonu, Mesane İrritasyonu ve Fonksiyonsuzluğunun tedavisi ile, Nöropatik Ağrı ve Kemokinin Tetiklediği ağrının tedavisi için de yararlıdırlar.
TR2008/00692T 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi. TR200800692T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number Publication Date
TR200800692T2 true TR200800692T2 (tr) 2008-03-21

Family

ID=23024747

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2008/00693T TR200800693T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi
TR2008/00692T TR200800692T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.
TR2008/00691T TR200800691T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
TR2003/01330T TR200301330T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2008/00693T TR200800693T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2008/00691T TR200800691T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların ya da durumların tedavi yöntemi.
TR2003/01330T TR200301330T2 (tr) 2001-02-15 2002-02-14 Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.

Country Status (39)

Country Link
US (10) US6967210B2 (tr)
EP (1) EP1368031A2 (tr)
JP (3) JP2004518711A (tr)
KR (3) KR20090005254A (tr)
CN (2) CN100522164C (tr)
AP (1) AP1749A (tr)
AR (1) AR035750A1 (tr)
AU (3) AU2002247200B9 (tr)
BR (1) BR0207272A (tr)
CA (1) CA2438712A1 (tr)
CO (1) CO5390085A1 (tr)
CR (1) CR7023A (tr)
CZ (1) CZ20032172A3 (tr)
EA (2) EA012409B1 (tr)
EC (1) ECSP024218A (tr)
EE (1) EE200300363A (tr)
GB (1) GB0119435D0 (tr)
HK (1) HK1080361B (tr)
HR (1) HRP20030652A2 (tr)
HU (1) HUP0303203A3 (tr)
IL (2) IL157341A0 (tr)
MA (1) MA26152A1 (tr)
ME (1) MEP21208A (tr)
MX (1) MXPA03006110A (tr)
MY (1) MY157745A (tr)
NO (1) NO20033622L (tr)
NZ (4) NZ544720A (tr)
OA (1) OA12549A (tr)
PA (1) PA8540101A1 (tr)
PE (1) PE20040175A1 (tr)
PL (1) PL363638A1 (tr)
SG (1) SG134170A1 (tr)
SK (1) SK10392003A3 (tr)
TR (4) TR200800693T2 (tr)
TW (1) TWI325319B (tr)
UA (2) UA80394C2 (tr)
WO (1) WO2002064126A2 (tr)
YU (1) YU62903A (tr)
ZA (1) ZA200306124B (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
MXPA05006656A (es) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc Metodos de tratamiento de desordenes de vejiga no dolorosos usando moduladores del canal de calcio subunidad (2o.
EP1589959A2 (en) * 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
CN102822979B (zh) * 2010-03-26 2015-08-26 株式会社半导体能源研究所 半导体器件
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
BR112013019265A2 (pt) * 2011-01-28 2016-10-11 Acorda Therapeutics Inc uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019126643A1 (en) * 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
CA3207205A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
FI95466C (fi) 1989-08-02 1996-02-12 Hoechst Roussel Pharma Menetelmä terapeuttisesti aktiivisten 2,3-dihydro-1-(pyridyyliamino)indolien valmistamiseksi
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
PT1056754E (pt) * 1998-01-29 2004-03-31 Bristol Myers Squibb Co Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
PL363638A1 (en) 2004-11-29
US20090281147A1 (en) 2009-11-12
CA2438712A1 (en) 2002-08-22
PA8540101A1 (es) 2003-09-05
PE20040175A1 (es) 2004-03-29
MEP21208A (en) 2010-06-10
NZ556697A (en) 2009-01-31
GB0119435D0 (en) 2001-10-03
ZA200306124B (en) 2004-11-08
AP2003002834A0 (en) 2003-09-30
AU2008201179A1 (en) 2008-04-03
AR035750A1 (es) 2004-07-07
ECSP024218A (es) 2003-09-24
TR200800693T2 (tr) 2008-07-21
US20040157889A1 (en) 2004-08-12
MXPA03006110A (es) 2005-07-01
US6967210B2 (en) 2005-11-22
NZ527011A (en) 2005-07-29
KR100951542B1 (ko) 2010-04-09
CN1529598A (zh) 2004-09-15
AU2002247200B2 (en) 2007-12-13
US20060025452A1 (en) 2006-02-02
JP2004518711A (ja) 2004-06-24
EP1368031A2 (en) 2003-12-10
US7230015B2 (en) 2007-06-12
UA88773C2 (ru) 2009-11-25
YU62903A (sh) 2006-05-25
IL157341A (en) 2010-11-30
US20040157888A1 (en) 2004-08-12
TR200301330T2 (tr) 2004-12-21
JP2009185045A (ja) 2009-08-20
KR20040014459A (ko) 2004-02-14
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
MY157745A (en) 2016-07-15
NO20033622D0 (no) 2003-08-14
KR100951540B1 (ko) 2010-04-09
EA200600896A1 (ru) 2006-08-25
KR20090005255A (ko) 2009-01-12
US20090270458A1 (en) 2009-10-29
US20050159456A1 (en) 2005-07-21
AU2002247200B9 (en) 2008-07-10
IL157341A0 (en) 2004-02-19
CN1679564A (zh) 2005-10-12
AU2008201179B2 (en) 2009-08-20
JP2010120958A (ja) 2010-06-03
NZ539159A (en) 2006-11-30
EA200300882A1 (ru) 2003-12-25
HK1080361A1 (zh) 2006-04-28
US20050234105A1 (en) 2005-10-20
WO2002064126A3 (en) 2003-02-20
EA012409B1 (ru) 2009-10-30
NZ544720A (en) 2007-08-31
CZ20032172A3 (cs) 2004-01-14
CR7023A (es) 2003-11-17
MA26152A1 (fr) 2004-07-01
NO20033622L (no) 2003-10-06
SG134170A1 (en) 2007-08-29
US7179821B2 (en) 2007-02-20
HUP0303203A3 (en) 2007-11-28
OA12549A (en) 2006-06-05
HUP0303203A2 (hu) 2003-12-29
UA80394C2 (en) 2007-09-25
HK1080361B (zh) 2009-10-30
AU2009238332A1 (en) 2009-12-10
EA011319B1 (ru) 2009-02-27
EE200300363A (et) 2003-10-15
KR20090005254A (ko) 2009-01-12
US7534803B2 (en) 2009-05-19
TR200800691T2 (tr) 2008-03-21
WO2002064126A2 (en) 2002-08-22
US20030105150A1 (en) 2003-06-05
CO5390085A1 (es) 2004-04-30
US20090209594A1 (en) 2009-08-20
AP1749A (en) 2007-06-13
CN100522164C (zh) 2009-08-05
BR0207272A (pt) 2004-02-10
US20090209595A1 (en) 2009-08-20
HRP20030652A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
TR200800692T2 (tr) Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
GB0225475D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
CY1108808T1 (el) Ενωσεις μοτιλιδης
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MXPA05011233A (es) Vectores peptidicos.
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
SE0101082D0 (sv) Novel use
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
PL372769A1 (en) Cyanoguanidine prodrugs
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
EA200301299A1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
MXPA03009506A (es) USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO.
UY27206A1 (es) Método de tratamiento de condiciones o enfermedades desmielinizantes
YU51802A (sh) Nova terapeutska primena enoksaparina
ITBO20000360A0 (it) Apparecchiatura di elettrostimolazione del corpo umano .
EA200500903A1 (ru) Силиловые простые эфиры
TH60984A (th) วิธีรักษาโรค หรือสภาวะจากการสูญเสียไมอีลิน
UA6623U (en) Method for increasing therapeutic efficacy of clays